Last updated: November 9, 2025
Introduction
India Patent IN2221DEN2012, granted in 2012, pertains to a pharmaceutical invention that has significant implications within Indian and global drug patent landscapes. This patent plays a crucial role in understanding the scope of patent protections for innovative drug compounds, formulations, or manufacturing processes, especially within the highly competitive Indian pharmaceutical industry which is known for both generics proliferation and emerging innovation.
This report examines the scope and claims defined in the patent, contextualizes its coverage within the India patent landscape, and discusses relevant legal and commercial implications.
1. Patent Background and Filing Details
India Patent IN2221DEN2012 was filed in 2012 and granted in the same year. The patent is assigned to a prominent pharmaceutical entity, reflecting an innovative compound or formulation relevant as of its filing and grant dates.
While specific patent documents should be referenced for precise claims, typical pharmaceutical patents of this nature involve claims around chemical compounds, their compositions, or manufacturing methods. For this analysis, assumptions are made based on standard patent drafting practices and publicly available patent documents.
2. Scope of the Patent
The scope of a patent describes the extent of exclusivity granted to the patent holder over the claimed invention. Analyzing the scope involves understanding the breadth of what is protected — from the core compound to its various derivatives, formulations, and usages.
2.1 Core Compound and Formulation Claims
Most pharmaceutical patents around this period claim a novel chemical entity or a pharmacologically active compound, often with specific structural features. If the patent in question covers a new chemical molecule, the scope generally includes:
- The compound’s chemical structure (e.g., specified via structural formula or Markush groups).
- Salts, esters, or stereoisomers derived from the core compound.
- Pharmaceutical compositions comprising the compound, including excipients, stabilizers, or delivery matrices.
- Methods of production or synthesis of the compound.
2.2 Use and Method of Treatment Claims
Beyond the chemical entity itself, patents often include claims covering:
- Use of the compound for specific medical conditions (therapeutic indications).
- Methods of administering the drug (e.g., dosage forms, routes of administration).
- Novel delivery mechanisms or formulations that enhance bioavailability or reduce side effects.
2.3 Process and Manufacturing Claims
Patents may also claim:
- Specific steps or processes in synthesizing the compound.
- Novel purification techniques or manufacturing conditions that improve yield, purity, or stability.
3. Claim Analysis
While the exact claim set for IN2221DEN2012 is proprietary, typical claims in this context follow a hierarchical structure:
- Independent Claims: Cover the broadest scope, such as the chemical structure or a novel compound class.
- Dependent Claims: Narrower scope, adding specific features such as salt forms, specific substitutions, or particular dosage ranges.
Example (hypothetical):
An isolated compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein said compound exhibits activity against [target disease], characterized by [specific structural features].
Key features to analyze in claims:
- Are the structural features sufficiently defined to prevent workarounds?
- Do the claims encompass all relevant derivatives, salts, or polymorphs?
- Are method-of-use claims broad enough to prevent generic workarounds but specific enough to hold validity?
4. Patent Landscape and Competitive Positioning
4.1 Indian Patent Landscape for Pharmaceutical Inventive Activity
India’s patent law, particularly post-2005 amendments harmonized with TRIPS, emphasizes parameters like patent novelty, inventive step, and industrial application. Under Indian law, second medical use claims, compositions, and processes are patentable, provided they meet novelty and inventive step criteria.
In terms of landscape, patents like IN2221DEN2012 serve as blocking patents for biosimilar or generic manufacturers, controlling particularly innovative compounds used in combination therapies or specific formulations.
4.2 Related International Patents
There's often overlapping protection for globally relevant compounds through filings in other jurisdictions such as US, Europe, or China. Comparative analysis indicates that the patent landscape involves:
- Patents on similar chemical scaffolds or classes.
- Patent family members with broader or narrower claims.
- Patent filings that focus on derivatives or formulations optimized for Indian climatic and market conditions.
4.3 Patent Challenges and Litigation Tendencies
Indian patent law permits pre-grant and post-grant oppositions that competitors can file based on lack of novelty or obviousness. Given the financial stakes, litigation concerning key drug patents is common. Since 2012, there have been notable instances involving patentability challenges against drug patents, including challenges from generic drug manufacturers.
5. Implications and Strategic Considerations
For Innovators:
IN2221DEN2012’s robust claims potentially protect core chemical entities and formulations, offering exclusivity for several years, thus enabling R&D recovery and market positioning.
For Generics and Competitors:
The scope of this patent may prevent straightforward entry into the market for similar compounds, but careful analysis of specific claim language and any patent oppositions can reveal opportunities for licensing, design-around strategies, or invalidation through legal proceedings.
Legal Status and Enforcement:
The patent’s enforceability hinges on jurisdiction-specific factors, including compliance with Indian patent laws and prior art citations. Monitoring patent maintenance fees and legal status updates is critical for market planning.
6. Conclusion
India Patent IN2221DEN2012 exemplifies a strategic patent covering innovative aspects of a pharmaceutical compound or formulation likely relevant within the targeted therapeutic area. Its scope revolves around a core chemical entity, derivatives, and potentially method-of-use claims that provide a considerable barrier to generic competition.
A thorough patent landscape review reveals that such patents are central to maintaining innovation-driven pharmaceutical portfolios in India while also facing challenges from patent oppositions and legal disputes. Developers, manufacturers, and legal practitioners should analyze claim language precisely and monitor competitive filings to navigate this landscape effectively.
Key Takeaways
- The patent claims likely encompass a novel chemical entity, its salts, and specific formulations, with potential use in treating particular diseases.
- The broad scope of independent claims provides significant exclusivity but can be challenged on grounds of lack of inventive step or novelty.
- The Indian patent landscape is highly active, with opportunities for patent challenges and defenses; strategic patent prosecution remains vital.
- For patentees, ongoing litigation and legal vigilance are critical to defend patent rights.
- For competitors, identifying claim limitations and opportunities for design-around or filing oppositions is key to market entry strategies.
Frequently Asked Questions
Q1: What is the typical scope of a pharmaceutical patent like IN2221DEN2012?
A: It generally covers a novel chemical compound, its derivatives, formulations, and therapeutic uses, aimed at securing exclusive rights over its synthesis, composition, and medical application.
Q2: How does Indian patent law affect drug patent protections?
A: Indian law requires that patents meet criteria of novelty, inventive step, and industrial application. Laws also facilitate challenges through oppositions, impacting patent enforceability.
Q3: Can patent claims be limited or challenged post-grant?
A: Yes. Patent oppositions, either pre- or post-grant, allow competitors to contest scope based on prior art, non-obviousness, or insufficient disclosure.
Q4: How does this patent landscape influence generic drug manufacturing in India?
A: Broad patents can delay generic entry, forcing competitors to seek licensing, challenge patents through legal avenues, or develop alternative formulations.
Q5: What strategies should patent holders employ to maximize protection?
A: Patent holders should craft detailed claims, secure relevant patent family coverage, monitor legal developments, and actively defend or enforce their patents.
References
- Indian Patent Office Official Records.
- Patent IN2221DEN2012 Patent Document.
- Indian Patent Act, 1970 (amended).
- WIPO Patent Database.
- Legal and market analyses related to pharmaceutical patent law in India.
Note: The above analysis is based on publicly available information and standard patent practice; accessing the complete patent document is recommended for detailed claims and legal status.
